Musculoskeletal Disorders Drugs Global Market Report 2018

1. Musculoskeletal Disorders Drugs Global Market Report 2018 Including: Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others Covering: F. Hoffmann-La Roche Ltd., GlaxosmithKline Plc, Pfizer Inc., Abbott Laboratories Inc., Daiichi Sankyo Company Limited Feb 2018

2. Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information. • Identify growth segments for investment. • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market. • Create regional and country strategies on the basis of local data and analysis. • Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors. • Develop strategies based on likely future developments. • Utilize the relationships between key data sets for superior strategizing. • Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market. • Report will be updated with the latest data and delivered to you within 3-5 working days of order. Scope Markets Covered: Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others Companies Mentioned: F. Hoffmann-La Roche Ltd., GlaxosmithKline Plc, Pfizer Inc., Abbott Laboratories Inc., Daiichi Sankyo Company Limited Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia. Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast. Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Musculoskeletal Disorders Drugs Indicators Comparison. Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments. Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

3. Musculoskeletal Disorders Drugs Musculoskeletal Disorders Drugs Market Characteristics Market Characteristics The musculoskeletal system drugs market comprises companies that discover, develop, manufacture and distribute medications used in the treatment of musculoskeletal diseases. Musculoskeletal diseases include arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing. Musculoskeletal system drugs are classified as the following – Antirheumatic drugs are used in the treatment of Muscle Relaxants are drugs that act on Others include drugs used in In this report market value is defined as the revenues organizations earn by selling their goods and services within the specified market, based on the price at which they sell. Only goods and services traded between entities are included. The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.

4. Musculoskeletal Disorders Drugs Musculoskeletal Disorders Drugs Market Market Historic Growth Historic Growth The global musculoskeletal disorders drugs market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%. The chart and table below shows the year-on-year growth of the global musculoskeletal disorders drugs market during 2013 – 2017. Drivers of the Market: Restraints on the Market:

5. Musculoskeletal Disorders Drugs Musculoskeletal Disorders Drugs Market Forecast Growth Market Forecast Growth The global musculoskeletal disorders drugs market is expected to grow from $XX billion in 2017 to $177 billion in 2021 at a compound annual growth rate (CAGR) of XX%. This can be attributed to the expected increase in healthcare awareness, number of surgical operations and prevalence of musculoskeletal disorders such as fibromyalgia, rheumatoid arthritis, osteoarthritis around the world. Also, increasing number of road accidents and workplace injuries are expected to contribute to market growth. The chart and table below shows the year-on-year growth of the global musculoskeletal disorders drugs market during 2017 - 2021. Drivers of the Market: Restraints on the Market:

6. Musculoskeletal Disorders Drugs Musculoskeletal Disorders Drugs Market Market Segmentation Segmentation The chart and table below shows the split of the musculoskeletal disorders drugs market in 2017. The total market value for musculoskeletal disorders drugs was $X billion in 2017. The markets that are covered include Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others. Drugs For Rheumatoid Arthritis was the X largest segment in the musculoskeletal disorders drugs market with X% share of the market. The market value for the drugs for rheumatoid arthritis was $X billion in 2017. Muscle Relaxants made up around X% share of the market. The market value for the muscle relaxants was $X billion in 2017.

7. Musculoskeletal Disorders Drugs Musculoskeletal Disorders Drugs Market Market Regional And Country Regional And Country Analysis Analysis The Asia Pacific was the largest region in the musculoskeletal disorders drugs market in 2017, musculoskeletal disorders drugs for $X billion or X% market share. North America was the x largest region musculoskeletal disorders drugs for $X billion or X% market share. Western Europe was the x largest region musculoskeletal disorders drugs for $X billion or X% market share.

8. Musculoskeletal Disorders Drugs Musculoskeletal Disorders Drugs Market Competitive Landscape Market Competitive Landscape The leading competitors in the global musculoskeletal disorders drugs market are F. Hoffmann-La Roche Ltd., GlaxosmithKline Plc, Pfizer Inc., Abbott Laboratories Inc., Daiichi Sankyo Company Limited. The chart and table below displays the percentage market share of the top players in the musculoskeletal disorders drugs market industry. F. Hoffmann-La Roche Ltd. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. GlaxosmithKline Plc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Pfizer Inc. generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year.

9. Abbott Laboratories Inc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Daiichi Sankyo Company, Limited generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Johnson & Johnson generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Sanofi S.A. generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Novartis AG generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Otsuka Pharmaceutical Co., Ltd. generated revenues of $XX4 billion for the financial year 2016, an XX% decrease from the previous year. Celgene Corporation generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Company Profile F. Hoffmann-La Roche Ltd. Overview Roche was the largest competitor in the musculoskeletal drugs market in 2017 with XX% share of the market. It is a multinational healthcare company that focuses on developing medicines and diagnostics. The company was founded in 1896 and is headquartered in Basel, Switzerland. Products and Services The company operates through the following divisions – The Pharmaceutical division develops, produces, and The Diagnostics division manufactures equipment and Strategy

10. Financial Performance Roche’s Pharmaceuticals Division, involved in musculoskeletal drugs manufacturing, generated revenues of CHF XX billion ($XX billion) for the financial year 2016, a XX% increase from the previous year. The company had a market GlaxosmithKline Plc Overview Products and Services Strategy Financial Performance Pfizer Inc. Overview Products and Services Strategy Financial Performance Abbott Laboratories Inc. Overview Products and Services Strategy Financial Performance Daiichi Sankyo Company Limited Overview Products and Services Strategy Financial Performance Roche’s strategy aims at developing new products by investing in R&D and strategic collaborations and agreements. For example, Bruton’s tyrosine kinase inhibitor (BTKi) and cadherin-11 antibody are